{"entity":{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","aka":["RASolve 301"],"tldr":"A phase 3 trial of Daraxonrasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.","summary":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) is a phase 3 interventional study registered as NCT06881784 by Revolution Medicines, Inc., with 590 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-12-01. Interventions recorded: daraxonrasib, docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06881784","url":"https://clinicaltrials.gov/study/NCT06881784"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","kras-inhibitors"],"targets":[],"drugs":["daraxonrasib","docetaxel"],"companies":["revolution-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06881784","phase":"3","setting":"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC","sponsor":"Revolution Medicines, Inc.","participation":[{"nct":"NCT06881784","source":"https://clinicaltrials.gov/study/NCT06881784","fetchedAt":"2026-10-07T16:55:12.940Z","studySha256":"0d4b2c950f84a9b0543049627a2dcb40f334e93987036b3722581b5ab20ebddc","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-29","leadSponsor":"Revolution Medicines, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":590,"enrolmentType":"ESTIMATED","siteCount":158,"recruitingSiteCount":158,"countries":["Australia","Belgium","France","Germany","Hong Kong","Ireland","Italy","Japan","Netherlands","New Zealand","Poland","Puerto Rico","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom","United States"]}],"started":"2025-05-06","startedType":"actual","enrolled":590,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06881784/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"}],"company":[{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/"}]}}